Sunovion Data Presentations At Annual American Psychiatric Association Meeting Showcase Growing Psychiatry Franchise
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) will present four research posters on Latuda® (lurasidone HCl) and one on novel drug candidate dasotraline at the 170th Annual Meeting of the American Psychiatric Association (APA), which will be held May 20-24, 2017, in San Diego, California.
LATUDA is an atypical antipsychotic agent approved in the U.S. for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate in adults and for the treatment of schizophrenia in adults and adolescents (13 to 17 years of age).
Dasotraline is a dopamine and norepinephrine reuptake inhibitor (DNRI) currently in development to evaluate its use in treating attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED).